---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107304"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:46:48.457841+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Metagenomi reports Q2 2025 cash $205M; hemophilia A IND/CTA submission planned for 2026

## Summary
- Cash, cash equivalents and marketable securities of $205.0M as of June 30, 2025; runway expected into 2027.
- R&D expenses of $22.5M (down 20% YoY); G&A expenses of $7.0M (down from $8.6M).
- MGX-001 hemophilia A program: IND/CTA submission planned in 2026; durable FVIII activity shown through 19 months in NHP study.
- Appointed Laurence Reid, Ph.D., to Board of Directors in August 2025; established an R&D Committee.
- Presented three abstracts at ASGCT on compact nucleases and CAST systems for targeted gene integration.

## SEC filing metadata
- accession: 0000950170-25-107304
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017025107304/0000950170-25-107304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017025107304/mgx-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107304
- JSON: https://secwatch.observer/filing/0000950170-25-107304.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.